{
  "ticker": "BIIB",
  "company_name": "Biogen Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT00801060",
      "title": "Evaluation of Safety and Efficacy of Fludarabine, Cyclophosphamide, and Rituximab (FCR) +/- Lumiliximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia (CLL)",
      "status": "TERMINATED",
      "phase": "PHASE2",
      "condition": "Chronic Lymphocytic Leukemia",
      "start_date": "2008-02",
      "completion_date": "2010-09",
      "enrollment": 0,
      "sponsor": "Biogen"
    },
    {
      "nct_id": "NCT02472938",
      "title": "Study to Explore the Onset of Efficacy on Magnetic Resonance Disease Activity of BG00012 (Dimethyl Fumarate) in Patients With Relapsing remitTing Multiple Sclerosis",
      "status": "WITHDRAWN",
      "phase": "PHASE4",
      "condition": "Relapsing Remitting Multiple Sclerosis",
      "start_date": "2015-07",
      "completion_date": "2020-07",
      "enrollment": 0,
      "sponsor": "Biogen"
    },
    {
      "nct_id": "NCT05058950",
      "title": "An Observational Study Using Multimodal Sensors to Measure Cognitive Health in Adults and Distinguish Mild Cognitive Impairment From Normal Aging",
      "status": "TERMINATED",
      "phase": "",
      "condition": "Mild Cognitive Impairment, Normal Aging",
      "start_date": "2021-09-20",
      "completion_date": "2023-09-19",
      "enrollment": 0,
      "sponsor": "Biogen"
    },
    {
      "nct_id": "NCT01677572",
      "title": "Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-A\u03b2 IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease",
      "status": "TERMINATED",
      "phase": "PHASE1",
      "condition": "Alzheimer's Disease",
      "start_date": "2012-10-05",
      "completion_date": "2019-07-31",
      "enrollment": 0,
      "sponsor": "Biogen"
    },
    {
      "nct_id": "NCT02269930",
      "title": "Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterferon Beta-1a) and Rebif\u00ae (Interferon Beta-1a) in Healthy Volunteers",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Multiple Sclerosis",
      "start_date": "2014-10",
      "completion_date": "2014-12",
      "enrollment": 0,
      "sponsor": "Biogen"
    },
    {
      "nct_id": "NCT01767311",
      "title": "A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's Disease",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Alzheimer's Disease",
      "start_date": "2012-12-20",
      "completion_date": "2024-12-10",
      "enrollment": 0,
      "sponsor": "Eisai Inc."
    },
    {
      "nct_id": "NCT01764594",
      "title": "Safety Study of CDP7657 in Patients With Systemic Lupus Erythematosus",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Immune System Diseases, Autoimmune Diseases, Lupus Erythematosus, Systemic, Skin and Connective Tissue Diseases, Connective Tissue Disease",
      "start_date": "2013-01",
      "completion_date": "2014-08",
      "enrollment": 0,
      "sponsor": "UCB Pharma"
    },
    {
      "nct_id": "NCT05265728",
      "title": "A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Participants With Relapsing-Remitting Multiple Sclerosis",
      "status": "TERMINATED",
      "phase": "PHASE3",
      "condition": "Multiple Sclerosis, Relapsing-Remitting",
      "start_date": "2022-04-26",
      "completion_date": "2024-05-27",
      "enrollment": 0,
      "sponsor": "Biogen"
    },
    {
      "nct_id": "NCT04580381",
      "title": "Real World Effectiveness of Natalizumab Extended Interval Dosing in a French Cohort",
      "status": "COMPLETED",
      "phase": "",
      "condition": "Multiple Sclerosis, Relapsing-Remitting",
      "start_date": "2020-09-01",
      "completion_date": "2021-10-30",
      "enrollment": 0,
      "sponsor": "University Hospital, Caen"
    },
    {
      "nct_id": "NCT02698267",
      "title": "Effect of Itraconazole on the Pharmacokinetics of BIIB074",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Neuropathic Pain",
      "start_date": "2016-02",
      "completion_date": "2016-04",
      "enrollment": 0,
      "sponsor": "Biogen"
    }
  ],
  "summary": {
    "total_trials": 50,
    "by_phase": {
      "PHASE2": 9,
      "PHASE4": 2,
      "": 8,
      "PHASE1": 18,
      "PHASE3": 9,
      "PHASE2, PHASE3": 1,
      "PHASE1, PHASE2": 2,
      "NA": 1
    },
    "by_status": {
      "TERMINATED": 11,
      "WITHDRAWN": 1,
      "COMPLETED": 35,
      "UNKNOWN": 1,
      "RECRUITING": 1,
      "ACTIVE_NOT_RECRUITING": 1
    },
    "active_trials": 2,
    "completed_trials": 35,
    "conditions": [
      "Alzheimer Disease, Progressive Supranuclear Palsy, Frontotemporal Dementia",
      "Alzheimer's Disease",
      "Amyotrophic Lateral Sclerosis",
      "Antibody-mediated Rejection",
      "Chronic Kidney Diseases, Alport Syndrome, Autosomal Dominant Polycystic Kidney",
      "Chronic Lymphocytic Leukemia",
      "Chronic Plaque Psoriasis",
      "Diabetic Nephropathy",
      "Healthy",
      "Healthy Volunteer",
      "Healthy Volunteers",
      "Hepatic Impairment, Healthy",
      "IgA Nephropathy, CKD Associated With Type 1 Diabetes, Focal Segmental Glomerulosclerosis, Autosomal Dominant Polycystic Kidney",
      "Immune System Diseases, Autoimmune Diseases, Lupus Erythematosus, Systemic, Skin and Connective Tissue Diseases, Connective Tissue Disease",
      "Immune System Diseases, Autoimmunity",
      "Inflammation and Pain Following Ocular Surgery",
      "Major Depression",
      "Major Depressive Disorder",
      "Mild Cognitive Impairment, Normal Aging",
      "Multiple Sclerosis",
      "Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting",
      "Multiple Sclerosis, Relapsing-Remitting",
      "Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis",
      "Multiple Sclerosis, Relapsing-Remitting, Relapsing-Remitting Multiple Sclerosis",
      "Neuropathic Pain",
      "Non-Hodgkin's Lymphoma",
      "Ovarian Cancer, Peritoneal Neoplasms",
      "Parkinson's Disease, Healthy",
      "Psoriasis",
      "Relapsing Remitting Multiple Sclerosis",
      "Relapsing-Remitting Multiple Sclerosis",
      "Relapsing-Remitting Multiple Sclerosis (RRMS)",
      "Renal Insufficiency, Chronic, Diabetes Mellitus, Type 2",
      "Spinal Muscular Atrophy"
    ],
    "lead_stage": "commercial"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:17:09.891508",
    "search_query": "Biogen Inc.",
    "url": "https://clinicaltrials.gov/search?term=Biogen+Inc."
  }
}